Xelpac 6 mg/ml Vial30 mg

Xelpac 6 mg/ml Vial is a taxane-class chemotherapy agent used in the treatment of several solid-organ malignancies. Its indications are classified below by strength of evidence.

Established / FDA-approved indications

• Ovarian carcinoma: First-line therapy (in combination with cisplatin) and second-line/subsequent therapy for advanced or metastatic carcinoma of the ovary.
• Breast cancer: Adjuvant treatment of node-positive breast cancer, administered sequentially after standard anthracycline-containing combination chemotherapy; and treatment of metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy.
• Non-small cell lung cancer (NSCLC): First-line treatment, in combination with cisplatin, for patients who are not candidates for potentially curative surgery and/or radiation therapy.
• AIDS-related Kaposi's sarcoma: Second-line treatment.

Combination-therapy dependent uses

Xelpac 6 mg/ml Vial is used together with other agents (most commonly a platinum compound such as cisplatin or carboplatin) for ovarian cancer and NSCLC; it is not intended as monotherapy in these settings.

Other (guideline-supported / off-label) uses

Guideline-supported off-label use of Xelpac 6 mg/ml Vial also occurs in some other solid tumours (e.g. certain gastric, cervical, endometrial, and head-and-neck cancers) as part of multidisciplinary oncology protocols; such use should be guided by an oncologist based on current treatment guidelines.

Each mL of Paclitaxel injection concentrate typically contains 6 mg of Paclitaxel, formulated in a vehicle of polyoxyethylated castor oil (Cremophor EL) and dehydrated alcohol (approximately 1:1, v/v). It is supplied as a sterile, non-aqueous concentrate in single-use vials of various strengths (e.g., 30 mg/5 mL, 100 mg/16.7 mL, 150 mg/25 mL, 300 mg/50 mL), intended for dilution before intravenous infusion.

Xelpac 6 mg/ml Vial is a semi-synthetic antineoplastic agent belonging to the taxane class, originally derived from the bark of the Pacific yew tree (Taxus brevifolia) and now produced by semi-synthesis. It is administered as an intravenous chemotherapy infusion under the supervision of an oncologist for the treatment of ovarian cancer, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.

Xelpac 6 mg/ml Vial works by binding to microtubules and preventing their normal breakdown, which blocks cell division and leads to death of rapidly dividing cancer cells.

Antineoplastic agent — Taxane (microtubule-stabilizing agent / mitotic inhibitor)

Pharmacodynamics

Paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes the resulting microtubules by preventing their depolymerisation. This abnormal stability disrupts the normal dynamic reorganisation of the microtubule network that is required for vital interphase and mitotic cell functions, leading to inhibition of cell division (arrest at the G2/M phase of the cell cycle) and, ultimately, apoptosis of rapidly dividing cells, including malignant cells.

Pharmacokinetics

Following intravenous infusion, Paclitaxel exhibits a biphasic decline in plasma concentrations and is extensively (>88%) bound to plasma proteins. It is metabolised mainly in the liver via cytochrome P450 enzymes CYP2C8 and, to a lesser extent, CYP3A4, and is eliminated predominantly through biliary/faecal excretion, with a smaller fraction excreted renally. Its pharmacokinetics can be schedule- and dose-dependent (e.g., differing between 3-hour and 24-hour infusions).

Xelpac 6 mg/ml Vial is for intravenous infusion only and must be administered in a healthcare facility equipped to manage severe hypersensitivity reactions, under the supervision of a physician experienced in cancer chemotherapy.

Premedication (required before every infusion)

• Corticosteroid (e.g., dexamethasone), given orally or intravenously approximately 12 and 6 hours, or 30–60 minutes, before Xelpac 6 mg/ml Vial per institutional protocol.
• An H1-antihistamine (e.g., diphenhydramine), given intravenously 30–60 minutes before.
• An H2-antagonist (e.g., cimetidine or ranitidine), given intravenously 30–60 minutes before.

Infusion technique

• Xelpac 6 mg/ml Vial must be diluted before use (see Reconstitution) and infused through tubing containing an in-line filter with a microporous membrane (pore size ≤0.22 micron).
• Infused over 3 hours or 24 hours depending on the protocol and indication.
• Vital signs are monitored closely, especially during the first 15 minutes and first hour, for signs of a hypersensitivity reaction.
• Avoid contact with plasticized polyvinyl chloride (PVC) equipment where non-PVC administration sets are recommended, to reduce leaching of plasticizer.
• Avoid extravasation; if it occurs, stop the infusion immediately and manage per institutional protocol.

Xelpac 6 mg/ml Vial is metabolised by cytochrome P450 enzymes CYP2C8 and CYP3A4, making it susceptible to clinically significant drug interactions.

• CYP2C8/CYP3A4 inhibitors (e.g., ketoconazole and other azole antifungals, certain macrolide antibiotics, protease inhibitors): may increase Xelpac 6 mg/ml Vial plasma levels and the risk of toxicity (e.g., myelosuppression, neuropathy).
• CYP2C8/CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may reduce Xelpac 6 mg/ml Vial plasma levels and efficacy.
• Cisplatin: when the two are combined, Xelpac 6 mg/ml Vial is administered before cisplatin; giving it after cisplatin increases myelosuppression and reduces Xelpac 6 mg/ml Vial clearance.
• Other myelosuppressive drugs or radiotherapy: additive bone-marrow suppression; blood counts should be monitored closely when used concurrently with Xelpac 6 mg/ml Vial.
• Live vaccines: should generally be avoided during and for a period after Xelpac 6 mg/ml Vial therapy because of immunosuppression; consult the treating physician.

Adverse effects of Xelpac 6 mg/ml Vial are common and dose/schedule-dependent. Serious reactions (hypersensitivity, bone marrow suppression, peripheral neuropathy) are discussed fully under Precautions and Warnings; only a brief mention is given here.

Very common (occur in most patients)

• Alopecia (hair loss) — occurs in nearly all patients.
• Myelosuppression, chiefly neutropenia (see Precautions and Warnings).
• Peripheral sensory neuropathy — numbness/tingling of hands and feet (see Precautions and Warnings).
• Myalgia and arthralgia, typically 2–3 days after infusion.
• Nausea, vomiting, diarrhoea, and mucositis (mouth sores).
• Mild hypersensitivity reactions such as flushing, rash, or mild dyspnoea (see Precautions and Warnings for severe reactions).

Common

• Elevated liver enzymes.
• Injection-site reactions (redness, swelling; extravasation can cause tissue injury).
• Fatigue and asthenia.

Uncommon/rare

• Cardiac conduction abnormalities, including asymptomatic bradycardia.
• Severe anaphylactoid hypersensitivity reactions (see Precautions and Warnings).
• Interstitial pneumonitis.

Xelpac 6 mg/ml Vial is a cytotoxic chemotherapy agent that can cause fetal harm and is contraindicated during pregnancy. Women of reproductive potential should use effective contraception during, and for a period after, treatment with Xelpac 6 mg/ml Vial; male patients with female partners of reproductive potential should also use effective contraception. If Xelpac 6 mg/ml Vial is used inadvertently during pregnancy, or if a patient becomes pregnant while on it, she should be informed of the potential risk to the fetus and referred for genetic counselling.

Xelpac 6 mg/ml Vial is contraindicated during breastfeeding because of the potential for serious adverse effects in the nursing infant; breastfeeding should be discontinued during treatment and is not recommended for a period after the last dose, on the advice of the treating physician.

Xelpac 6 mg/ml Vial must be administered only under the supervision of a physician experienced in the use of cancer chemotherapeutic agents, in a facility equipped to manage life-threatening complications.

Severe hypersensitivity reactions

Severe hypersensitivity reactions, including dyspnoea, hypotension requiring treatment, angioedema, and generalised urticaria, have occurred with Xelpac 6 mg/ml Vial, occasionally despite premedication. All patients must be premedicated with a corticosteroid, an H1-antihistamine, and an H2-antagonist prior to every infusion of Xelpac 6 mg/ml Vial (see Administration). Patients with a history of severe hypersensitivity to Xelpac 6 mg/ml Vial should not be re-challenged (see Contraindications). Fatal reactions have occurred rarely in patients despite premedication.

Bone marrow suppression

Xelpac 6 mg/ml Vial commonly causes dose-dependent bone marrow suppression, primarily neutropenia, which can be severe. Frequent monitoring of peripheral blood counts is required during treatment. Xelpac 6 mg/ml Vial should not be re-administered until neutrophils recover to at least 1,500 cells/mm³ (1,000 cells/mm³ for Kaposi's sarcoma) and platelets recover adequately; dose reduction may be needed for subsequent cycles.

Peripheral neuropathy

Peripheral neuropathy is frequent and dose-related. Patients should be monitored for numbness, tingling, burning, or weakness in the hands and feet; dose reduction or discontinuation may be required for severe or worsening neuropathy.

Other warnings

• Hepatic impairment: patients with hepatic impairment are at increased risk of toxicity; dose adjustment and close monitoring are recommended.
• Cardiac effects: conduction abnormalities (including bradycardia) may occur; cardiac monitoring is advised in patients with pre-existing conduction disturbances.
• Injection-site reactions/extravasation: may cause local tissue injury; administer via a secure, well-placed intravenous line and monitor the infusion site.
• Embryofetal toxicity: see Pregnancy and Lactation.
• Combination with radiotherapy or other myelosuppressive agents: additive bone-marrow suppression; see Interactions.

There is no known antidote for Xelpac 6 mg/ml Vial overdosage. Anticipated complications of overdose include exaggerated forms of the drug's known toxicities: severe bone marrow suppression, peripheral neurotoxicity, and mucositis. In case of suspected overdose of Xelpac 6 mg/ml Vial, the patient should be monitored closely in a hospital setting and managed with supportive care; seek immediate medical attention or contact emergency services/poison control without delay. Do not attempt to manage a suspected overdose at home.

Store unopened Xelpac 6 mg/ml Vial vials at controlled room temperature, below 30°C (ideally 20–25°C), in the original carton to protect from light. Do not freeze. Diluted infusion solutions of Xelpac 6 mg/ml Vial should be used within the time and conditions specified by institutional protocol/manufacturer instructions. Keep out of reach of children. Xelpac 6 mg/ml Vial should be prepared, handled, and disposed of by trained personnel using appropriate hazardous-drug precautions.

Hepatic impairment

Patients with hepatic impairment have a higher risk of toxicity with Xelpac 6 mg/ml Vial; dose adjustment based on bilirubin/transaminase levels and infusion schedule is recommended, per institutional protocol.

Renal impairment

Data are limited; Xelpac 6 mg/ml Vial should be used with caution in patients with significant renal impairment, with close monitoring.

Elderly patients

Elderly patients may be more likely to experience peripheral neuropathy, arthralgia, and cardiovascular events with Xelpac 6 mg/ml Vial; use with appropriate monitoring.

Pediatric patients

Safety and efficacy of Xelpac 6 mg/ml Vial have not been established in pediatric patients; its use is generally not recommended in this population outside of clinical trials.

Pregnancy and breastfeeding

See Pregnancy and Lactation for full detail — Xelpac 6 mg/ml Vial is contraindicated in both settings.

Xelpac 6 mg/ml Vial is administered in cycles (commonly every 2–3 weeks) for a number of cycles determined by the indication, treatment protocol, and the patient's response and tolerance — for example, a defined number of adjuvant cycles for breast cancer, or repeated cycles for metastatic/advanced disease until disease progression, unacceptable toxicity, or completion of the planned course. The exact duration of Xelpac 6 mg/ml Vial treatment must be individualised by the treating oncologist and should not be shortened or extended without medical advice.

Xelpac 6 mg/ml Vial injection concentrate is supplied ready-to-dilute and must be diluted prior to intravenous infusion — it is not a powder requiring reconstitution. It should be diluted in 0.9% Sodium Chloride Injection, 5% Dextrose Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, or 5% Dextrose in Ringer's Injection, to a final concentration of 0.3–1.2 mg/mL. Once diluted, Xelpac 6 mg/ml Vial solutions may develop slight haziness, which is attributable to the formulation vehicle and does not indicate reduced potency. The diluted solution must be administered through tubing containing an in-line microporous filter (pore size ≤0.22 micron) and used within the time limits specified by institutional protocol, as it does not contain a preservative.

Antineoplastic agents; Taxanes; Mitotic inhibitors / Microtubule-stabilizing agents

Paclitaxel binds to the beta-subunit of tubulin within microtubules and promotes their assembly while inhibiting depolymerisation. This results in abnormally stable microtubule bundles and disrupts the normal dynamic reorganisation of the microtubule network that cells require for interphase functions and mitosis. The disrupted mitotic spindle formation arrests affected cells at the G2/M phase of the cell cycle, ultimately triggering programmed cell death (apoptosis), which underlies the antitumour activity of Paclitaxel against rapidly dividing malignant cells.

D

The safety and efficacy of Xelpac 6 mg/ml Vial in pediatric patients have not been established. Xelpac 6 mg/ml Vial is not routinely recommended for use in children outside of a clinical trial setting, and any such use should be directed by a pediatric oncologist experienced with cytotoxic chemotherapy.